No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers by Møller, Pål et al.
H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(2) 67
Hereditary Cancer in Clinical Practice 2007; 5(2) pp. 67-71
No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1Mutation Carriers
Pål Møller
1, Lovise Mºhle
1, Neal Clark
1, Jaran Apold
2
1Section for Inherited Cancer, Department of Medical Genetics, Rikshospitalet-Radiumhospitalet Medical Center Oslo, Norway
2Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway
Key words: BRCA1, modifiers, expression, genetic counselling
Corresponding author: Pål Møller, M.D. Ph.D., Section for Inherited Cancer, The Norwegian Radium Hospital, 
N-0310 Oslo, Norway, e-mail: pmoller@ulrik.uio.no
Submitted: 13 February 2007
Accepted: 7 May 2007
A Ab bs st tr ra ac ct t
Modifying factors might theoretically determine whether a BRCA1 mutation carrier contracts breast or ovarian
cancer. If so, one would expect concordance for breast or ovarian cancer in affected sibships. We identified 
64 pairs with cancers where one or both sisters were demonstrated to carry a BRCA1 mutation, and 116 additional
constructed pairs in sibships with three or more affected sisters. We analysed concordance for breast and for
ovarian cancer both in the complete series and in the 64 sister pairs alone. The results were that concordance
for both breast and ovarian cancer in sisters was in keeping with random distribution or multiple and frequent
modifying genetic factors. In conclusion, there may be no major modifying factor of expression of BRCA1
mutations. The practical implication of our findings is that previous disease manifestations in close relatives may
have no bearing on the first cancer to be expected in a young female mutation carrier.
I In nt tr ro od du uc ct ti io on n
Breast and ovarian cancers are both expressions of
BRCA1 germ-line mutations. There have been
speculations whether or not modifying factors may
determine whether a mutation carrier contracts breast
or ovarian cancer. There are reports on environmental
factors having such effects in the population and/or in
BRCA1 mutation carriers (oral contraceptives, etc.) 
[1-2], natural variations in sex hormones (childbirth, etc.)
[3], and also lifestyle [4]. Germline BRCA1 mutations
(OMIM +113705) cause breast and/or ovarian cancer.
Besides sex and highly penetrant mutations, there are
no described major predictor factors determining who
is to contract breast cancer, or when she might do so.
Whether the position of the mutation within each gene
is indicative of what kind of cancer a BRCA mutation
carrier may contract has been discussed [5-7].
The possibility of genetic modifiers of expression of
BRCA1 mutations is important for three reasons:
1. Does a BRCA1 mutation carrying sister or daughter
to an ovarian or breast cancer patient have higher
risk for ovarian or breast cancer, respectively, than
other BRCA1 mutation carrying women? Such
questions are frequently asked during genetic
counselling. Because health care with respect to
oophorectomy and mastectomy is a personal
choice, lack of evidence may lead to intervention
based on unsubstantiated fear. Besides the obvious
problems with decision making in the absence of
knowledge, the fear itself may be considered 
a health problem.
2.  The other question is cost/benefit of research
programmes to look for modifiers of penetrance or
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3. The third question is whether the family history may
indicate which mutations to look for when performing
mutational analyses in a new family.
Also, if there are environmental factors influencing
BRCA1 expression, they should be present and subject
to identification within concordant pairs. If so, this may
be a way to identify behaviour patterns to avoid
contracting breast or ovarian cancer.
We addressed these questions by examining our
BRCA1 mutation carrying kindreds for whether there
was an association between the expression of the
mutations between sisters. If an association could be
demonstrated, there might be single modifiers
determining which cancer a mutation carrying woman
may contract. If not, there may not be modifiers of
clinical significance to predict which expression of 
a BRCA1 mutation a given woman is likely to contract.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s
BRCA1 genetic variants including frameshift, stop
and large deletions/insertions were scored as
“mutations”. Most of the Norwegian BRCA1 mutation
carriers have one out of a few frequent mutations 
[8-9]. We arranged high capacity testing for the
frequent mutations and expanded the pedigrees for all
new mutation carriers demonstrated. All diagnoses in
the families were verified in hospitals’ medical files or
in the Norwegian Cancer Registry. We offered all
families predictive testing. Information flow in the family
was good, and uptake of testing about 80% [10]. All
mutation carriers were offered follow-up examinations
aiming at early diagnosis and treatment, which apart
from a marginal personal fee is paid by the state
insurance. All activities were health services, all women
were given genetic counselling and all testing was
subject to written informed consent according to
national legislation. All confirmation of diagnoses in
medical files or cancer registry was subject to written
informed consent. All BRCA1 mutation carrying
kindreds were included. For all members of any
kindred, we record mother’s and father’s identity within
the pedigree structure, allowing us to identify all sister
pairs. All information was kept and analysed in our
computerized medical files (application written in dB+,
data kept in Oracle © format), analysed by means of
TOAD © and no research registry was created.
We identified all female BRCA1 mutation carriers
who had or had had one or more sisters in our medical
files and verified all their diagnoses. To avoid distorted
results because of prophylactic oophorectomy recently
advocated to mutation carriers, we censored all data
at the end of 2004.
BRCA1 mutation carriers frequently contract more
than one primary cancer – they may demonstrate
bilateral breast cancer and/or both breast and ovarian
cancer. Because the probability of developing more
than one cancer is influenced by the probability of
surviving the first one, and because treatment given to
cure the first cancer may influence the probability of
contracting a second primary, we decided to score
primary cancers only. Each woman was scored as
having breast or ovarian cancer as her first cancer. All
but one of those selected for the present study were
registered as having breast or ovarian cancer as the
first or only cancer. In one woman, breast cancer was
diagnosed when she was initially treated for ovarian
cancer. She was scored as having ovarian cancer.
Both breast and ovarian cancers may be lethal, and
their prognosis may differ. All available affected sisters
were tested. We did not have access to testing of
deceased patients, and included all sibships where one
or more of the affecteds had a demonstrated BRCA1
mutation. Obviously, affected pairs demonstrated to
be discordant for BRCA1 mutations were excluded.
In some families, we identified sibships with three
or more affected sisters. A triplet gives three possible
pairs, etc. We analysed the material twice:
• Initially, we analysed all affected pairs, ignoring all
triplets and quadruplets. Such an analysis will reduce
sample size and power, but may not disturb outcome
if a modifying factor had no association with numbers
of daughters.
• Thereafter, we repeated the analyses also including
all possible pairs within affected triplets and
quadruplets. In principle, this may give factors inside
triplets and quadruplets more weight in the analyses
because each person was counted more than once.
Expected numbers of breast-breast and ovarian-
-ovarian cancer pairs were calculated as the square of
the prevalence of each cancer in the total series
multiplied by the number of pairs in the series. Expected
numbers of breast-ovarian/ovarian-breast cancer pairs
were calculated as twice the product of the prevalence
of breast cancers multiplied by prevalence of ovarian
cancers in the series and multiplied by the number of
pairs in the series.
R Re es su ul lt ts s
P Pa ai ir rs s
We identified 64 pairs with breast or ovarian
cancers as first cancers in sibships with two affecteds,
and where at least one of the affecteds had 
a demonstrated BRCA1 mutation (Table 1).H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(2) 69
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T Ta ab bl le e   1 1. .   Sibships with two affected sisters. Number of patients with breast or ovarian cancer, calculated frequency, calculated expected
pairs concordant for given phenotype assuming random distribution, observed number of concordant pairs, and results of test for
independence
C Ca an nc ce er r N Nu um mb be er r    F Fr re eq qu ue en nc cy y E Ex xp pe ec ct te ed d   c co on nc co or rd da an nt t   p pa ai ir rs s O Ob bs se er rv ve ed d    C Ch hi i   s sq qu ua ar re e   ( (p p) )
o of f   p pa at ti ie en nt ts s c co on nc co or rd da an nt t   p pa ai ir rs s
breast 78 78/128=0.61 64x(0.61)
2=23.8 22 0.13 (>0.05)
ovarian 50 50/128=0.39 64x(0.39)
2=9.8 8 0.32 (>0.05)
T Ta ab bl le e   2 2. .   As Table 1, but also including all constructed pairs from triplets and quadruplets
C Ca an nc ce er r N Nu um mb be er r    F Fr re eq qu ue en nc cy y E Ex xp pe ec ct te ed d   c co on nc co or rd da an nt t   p pa ai ir rs s O Ob bs se er rv ve ed d    C Ch hi i   s sq qu ua ar re e   ( (p p) )
o of f   p pa at ti ie en nt ts s c co on nc co or rd da an nt t   p pa ai ir rs s
breast 209 209/360=0.58 180x(0.58)
2=60.7 63 0.09 (>0.05)
ovarian 151 151/360=0.42 180x(0.42)
2=31.7 34 0.17 (>0.05)
C Co on ns st tr ru uc ct te ed d  p pa ai ir rs s  f fr ro om m  t tr ri ip pl le et ts s  a an nd d  q qu ua ad dr ru up pl le et ts s
We identified 116 additional constructed pairs
representing all possible pairs from affected triplets and
quadruplets (Table 2).
As seen in Table 1 and Table 2, the expected
numbers of concordant pairs closely met the observed
numbers. Moreover, the observed numbers of
concordant pairs were slightly less than expected when
calculating for two-affected sibships only, which is
opposite to the hypothesis tested that there may be an
excess of concordant pairs.
D Di is sc cu us ss si io on n
The results were in keeping with the interpretation
that in BRCA1 mutation carriers, breast and ovarian
cancer are independently occurring: whether two BRCA1
mutation carrying sisters will contract the same or
different kinds of cancer appears to be stochastic. If so,
cancer type in a BRCA1 mutation carrying woman may
have no bearing on what is to be expected in her
mutation carrying sister. Phenotypes of cancers previously
registered in the kindred may have no bearing on what
to expect in a healthy young mutation carrier. This
interpretation has a direct bearing on genetic counselling
sessions where BRCA1 mutation carrying women have
to decide what to do. This interpretation was derived
directly from the observations and included no
assumptions on the underlying mechanism(s).
Numbers were small, but possibly large enough to
reveal any major factor. Autosomally, recessively inherited
modifying factors are assumed to produce sib
concordance without parent-offspring concordance.
Autosomally, dominantly inherited modifiers are assumed
to produce both parent-offspring and sib concordance.
Multifactorial factors modifying penetrance (genetic
and/or environmental) would be assumed to give more
concordance between sibs than parent-offspring. In this
way, both interaction caused by monogenic mechanism(s)
as well as multifactorially caused influence(s) were
assumed to produce sister correlation. The results were
that no signs of such modifiers were seen.
Multiple factors with low penetrance of each factor
may in analyses mimic random distributions. In real-life
practice, however, this problem is of less importance,
because the empirical observation without any
assumption was that cancer type in one affected will not
predict cancer type in her sister. In a scientific framework
the problem is difficult to address: Multifactorial
inheritance may not be described by genetic linkage,
and if sister concordance appears random, affected sib
pair approaches may be difficult as well. If concordance
had been found, we would have used the concordant
pairs to look for presence of modifying factors – the
results give such a strategy lower probability for success.
The majority of the pairs had one of the frequent
Norwegian BRCA1 mutations. If some of these mutations
carried risk for breast cancer only, and some for ovarian
cancer only, concordance between pairs should have
been observed. The lack of observed concordance
indicates that the mutations causing cancers in the
sibships carried no differences in expression with respect
to breast and ovarian cancer. This leads to the notion
that family history of distribution of breast and ovarian
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to look for. Obviously, the number of frequent mutations
examined was low, and to exclude a position effect as
reported by others [5] it would have been beneficial to
have a wider variation in frequently occurring mutations
within the cohort examined.
There are a number of ascertainment and statistical
problems in an analysis like this:
• We did not restrict the analyses to pairs where both
sisters had a demonstrated BRCA1 mutation,
because breast and ovarian cancer may carry
different prognoses. Concordance when both were
alive and testable might reflect that one type of
cancer has a better chance to survive.
• We did not analyse age at onset of disease, because
early age at onset was a selection criterion to
ascertain the families examined.
• As discussed initially, we did not consider second or
third primary cancers.
• There is a possibility that an untested affected woman
to a BRCA1 carrier does not carry the mutation. We
applied no correction for this probability. Because
breast cancer is more frequent in the general
population, a slight concordance for breast cancer
might have been expected. On the other hand,
ovarian cancer in the family may induce BRCA1
testing, and may artificially increase concordance
for ovarian cancer also when the ovarian cancer
patient was dead and not testable.
• Chemoprevention (tamoxifen, etc.) will invalidate 
a study like this. Chemoprevention for breast cancer
is not allowed in Norway and had not been used in
the cohort studied.
• Prophylactic oophorectomy and mastectomy may
invalidate a study like this. The uptake of prophylactic
mastectomy in Norway has been low. Until a few years
ago we conducted a large observational study for
early diagnosis of ovarian cancer and prophylactic
oophorectomy was rarely performed, while most older
mutation carriers today choose oophorectomy. In
principle, this was a retrospective study; disturbances
in outcome produced as an effect of our interventions
in the last decade were marginal, because our
intervention in principle was early detection and not
chemoprevention or prophylactic surgery. We observed
a total of no more than six breast cancers in BRCA1
mutation carriers after oophorectomy, and no ovarian
cancer in women who had had prophylactic
mastectomy. Because we considered first cancer only,
oophorectomy or mastectomy after first cancer will not
affect the results.
We considered our material informative and probably
not significantly influenced by  confounders making such
studies difficult. We may not wait to arrive at larger
numbers included, because the series has now become
invalidated by prophylactic surgery. Because we have
high compliance, because we have documented close
to all cancers in the families in the medical files and/or
cancer registries, because our families are large, thereby
minimizing the effect of calculation on the selection
clusters in the families, because we have complete
pedigree structures for close to all pedigrees in question,
and because we know that we have tested many or all
living affecteds in the present generations, we find that
our findings support the notion that there may be no
major modifying factor. Modifying factors – if they exist
– may be multiple and frequently occurring. Common,
low-penetrant genes causing familial breast cancer in
the absence of BRCA1 or BRCA2, and simultaneously
acting as modifiers of penetrance for BRCA1 and BRCA2,
have been suggested [11-12]. However, the reports do
not indicate a similar volume of genes besides BRCA1
and BRCA2 causing inherited ovarian cancer. Thus, to
make the model fit our findings, such modifiers may
produce breast cancer and not ovarian cancer in the
absence of BRCA1 or BRCA2.
In conclusion, observed phenotypes in the family
may not indicate which cancer a BRCA1 mutation
carrier is at risk for and family history may give no clue
as to which mutation to search for in breast-ovarian
cancer kindreds. With respect to genetic counselling,
this means that in kindreds with predominantly ovarian
cancer, the cancer to consider in a young BRCA1
carrier is breast cancer because breast cancer occurs
at an earlier age. In BRCA1 mutation carrying kindreds
with breast cancer alone, the risk for ovarian cancer
may be as high as in ovarian cancer kindreds.
R Re ef fe er re en nc ce es s
1. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H,
Provencher D, Radice P , Evans G, Bishop S, Brunet JS, Ponder BA.
Oral contraceptives and the risk of hereditary ovarian cancer.
Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med
1998; 339: 424-428.
2. Narod SA, Dubé MP , Klijn J, Lubinski J, Lynch HT, Ghadirian P ,
Provencher D, Heimdal K, Moller P , Robson M, Offit K, Isaacs C,
Weber B, Friedman E, Gershoni-Baruch R, Rennert G, Pasini B,
Wagner T, Daly M, Garber JE, Neuhausen SL, Ainsworth P ,
Olsson H, Evans G, Osborne M, Couch F, Foulkes WD, Warner E,
Kim-Sing C, Olopade O, Tung N, Saal HM, Weitzel J, Merajver S,
Gauthier-Villars M, Jernstrom H, Sun P , Brunet JS. Oral
contraceptives and the risk of breast cancer in BRCA1 and
BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94: 1773-
1779.
3. Jernstrom HC, Olsson H, Borg A. Reduced testosterone, 17
beta-oestradiol and sexual hormone binding globulin, and
increased insulin-like growth factor-1 concentrations, in healthy
nulligravid women aged 19-25 years who were first and/or
second degree relatives to breast cancer patients. Eur J Cancer
Prev 1997; 6: 330-340.
Pål Møller, Lovise Mºhle, Neal Clark, Jaran ApoldH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(2) 71
No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
4. Brunet JS, Ghadirian P , Rebbeck TR, Lerman C, Garber JE, 
Tonin PN, Abrahamson J, Foulkes WD, Daly M, Wagner-Costa-
las J, Godwin A, Olopade OI, Moslehi R, Liede A, Futreal PA,
Weber BL, Lenoir GM, Lynch HT, Narod SA. Effect of smoking
on breast cancer in carriers of mutant BRCA1 or BRCA2 genes.
J Natl Cancer Inst 1998; 90: 761-766.
5. Gayther SA, Mangion J, Russell P , Seal S, Barfoot R, Ponder BA,
Stratton MR, Easton D. Variation of risks of breast and ovarian
cancer associated with different germline mutations of the
BRCA2 gene. Nat Genet 1997; 15: 103-105.
6. Thompson D, Easton DF. Breast Cancer Linkage Consortium.
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer
Inst 2002; 94: 1358-1365.
7.  Easton DF, Ford D, Bishop DT. Breast Cancer Linkage
Consortium. Breast and ovarian cancer incidence in BRCA1-
-mutation carriers.  Am J Hum Genet. 1995; 56: 265-271.
8. Moller P , Heimdal K, Apold J. Norwegian Inherited Breast Cancer
Group; Norwegian Inherited Ovarian Cancer Group. Genetic
epidemiology of BRCA1 mutations in Norway. Eur J Cancer
2001; 37: 2428-2434.
9.  Heimdal K, Maehle L, Apold J. The Norwegian founder
mutations in BRCA1: high penetrance confirmed in an incident
cancer series and differences observed in the risk of ovarian
cancer. Eur J Cancer 2003; 39: 2205-2213.
10. Bodd TL, Reichelt J, Heimdal K, Moller P . Uptake of BRCA1
genetic testing in adult sisters and daughters of known mutation
carriers in Norway. J Genet Couns 2003; 12: 405-417.
11. Antoniou AC, Pharoah PD, McMullan G. Evidence for further
breast cancer susceptibility genes in addition to BRCA1 and
BRCA2 in a population-based study. Genet Epidemiol 2001;
21: 1-18.
12. Antoniou AC, Gayther SA, Stratton JF et al. Risk models for
familial ovarian and breast cancer. Genet Epidemiol 2000; 18:
173-190.